This information is intended for use by health professionals
Benylin Dry & Tickly Cough Syrup
per 5 ml
Excipients with known effect:
Propylene glycol (E1520)
Sodium benzoate (E211)
For the full list of excipients, see section 6.1.
For the relief of irritating, tickling dry coughs and sore throats.
Adults and children over 5 years: 10 ml
Children 1 – 5 years: 5 ml
The dose may be repeated three or four times a day.
Children under one year: Not to be given to children under 1 year.
There is no need for dosage reduction in the elderly.
Method of administration:
For oral use.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Do not give to children under one year.
Diabetics should take note that sucrose and glycerol may affect blood sugar levels.
Information relating specifically to excipients in the formulation.
This medicine contains sucrose and glucose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
This medicine contains 24 mg propylene glycol in each 5 ml which is equivalent to 4.8mg/ml.
This medicine contains 10 mg sodium benzoate (E211) in each 5ml
This medicine contains 5 mg of alcohol (ethanol) in each 5 ml dose. The amount in 5 ml of this medicine is equivalent to less than 1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects.
This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially 'sodium-free'.
If symptoms persist for more than 3 days or get worse, patients should stop use and consult a doctor.
No clinically significant interactions known.
The safety of this product during pregnancy and lactation has not been established, but is not considered to constitute a hazard during these periods.
This medicine has no or negligible influence on the ability to drive and use machines.
No known adverse effects.
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Treatment should be symptomatic and supportive.
Pharmacotherapeutic group: Cough suppressants and mucolytics, ATC code: R05FB01
Glycerol and sucrose have demulcent propertiese and will soothe irritated sore throats and possibly block sensory cough receptors within the respiratory tract.
Glycerol is readily absorbed from the gastrointestinal tract.
Sucrose is hydrolysed in the small intestine by the enzyme sucrase to glucose and fructose which are then absorbed.
Glycerol combines with free fatty acids in the liver to form triglycerides which are distributed to adipose tissues.
There are limited data on the distribution of oral sucrose in man.
Glycerol undergoes extensive metabolism principally in the liver and to a lesser extent in the kidneys. Glycerol is metabolised to glucose or glycogen or oxidised to carbon dioxide and water. The hydrolysis products of sucrose are metaboliszed through different pathways in the body. Glucose elicits a glycaemic and insulinaemic response that stimulates its update into cells while fructose is mainly metaboliszed in the liver via an insulin-independent pathway not regulated by energy supply. Fructose may be converted into trioses that can be used for the de novo synthesis of triglycerides and cholesterol.
It may also be excreted in the urine unchanged.
Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Citric acid monohydrate
Sodium benzoate (E211)
Cough syrup 513277 flavour (containing anise oil, liquorice, propylene glycol (E1520), ethanol (alcohol))
This medicinal product does not require any special storage conditions.
A white flint glass bottle with an aluminium roll-on pilfer proof cap with a flowed in liner, or a triseal (LDPE/EPE/LDPE) liner.
Alternative cap: A wadless polypropylene tamper evident cap.
Pack size: 200 ml
An amber glass bottle with an aluminium roll-on pilfer proof cap with a triseal (LDPE/EPE/LDPE) liner.
Pack size: 125ml or 150ml
An amber PET bottle with a child resistant polypropylene cap fitted with an expanded polyethylene liner.
Alternative cap: An aluminium roll-on pilfer proof cap with a flowed in liner, or a triseal (LDPE/EPE/LDPE) liner.
Pack size: 150ml or 300ml.
Not all pack sizes may be marketed.
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
McNeil Products Limited
50 - 100 Holmers Farm Way
11th January 2005
10 March 2021